New Published Data Confirms Galderma's Nemluvio Improves Itch And Sleep In 48 Hours

Galderma published post‑hoc analyses from its pivotal phase III ARCADIA (atopic dermatitis, >1,700 patients) and OLYMPIA (prurigo nodularis, 560 patients) programs showing nemolizumab (Nemluvio) produced rapid, clinically meaningful relief of itch and sleep disturbance within 48 hours — itch reduced by ~10.7% vs 2.9% (AD) and 17.2% vs 3.7% (PN), and sleep disturbance improved ~9.9% vs 4.6% (AD) and 13.4% vs 4.3% (PN) — with ~25% of AD and >33% of PN patients achieving meaningful responses by Day 14. Nemluvio, approved in the U.S. for PN (Aug 2024) and for AD patients ≥12 (Dec 2024), has generated $263m in net sales in the first nine months of 2025; Galderma, which holds ex‑Japan/Taiwan rights (where Maruho markets Mitchga), has already raised full‑year guidance to 17.0–17.7%, underscoring a commercial ramp and upside for revenue and market share in dermatology.

Analysis

Galderma released post-hoc analyses from its ARCADIA (>1,700 patients) and OLYMPIA (560 patients) phase III programs showing nemolizumab (Nemluvio) produced rapid, clinically meaningful relief of itch and sleep disturbance within 48 hours. In atopic dermatitis (AD) itch declined ~10.7% with nemolizumab versus 2.9% for placebo and in prurigo nodularis (PN) itch declined 17.2% versus 3.7%; sleep-disturbance improvements were ~9.9% versus 4.6% (AD) and 13.4% versus 4.3% (PN).

By Day 14 approximately 25% of AD patients and more than a third of PN patients achieved clinically meaningful responses in both itch and sleep, supporting the product’s symptomatic differentiation. Nemluvio received U.S. approvals for PN (Aug 2024) and for AD patients ≥12 (Dec 2024), generated $263 million in net sales in the first nine months of 2025, and Galderma has raised full-year guidance to 17.0–17.7% from a prior 12–14% on an expected ramp-up.

The analyses are post-hoc, which tempers the strength of causal claims and elevates the importance of prospective real-world uptake, payer coverage and longer-term safety/durability data as commercialisation scales. Shares traded at CHF160.50, down 0.93% on the report; sentiment is moderately positive with a modest market-impact score (0.38), and key near-term risks include reimbursement, geographic penetration (Galderma holds rights ex-Japan/Taiwan), and competitive dynamics.

Key Decisions for Investors

• Consider constructive exposure to Galderma given Nemluvio's rapid symptomatic benefit, U.S. approvals and $263m YTD sales alongside raised FY guidance, but size positions to reflect commercialization execution risk
• Monitor upcoming quarterly Nemluvio sales, payer coverage announcements and real-world uptake as primary catalysts and be prepared to trim or hedge if sequential sales or access metrics disappoint
• Prioritise surveillance of longer-term safety and durability data and competitive/regional dynamics (ex-Japan/Taiwan rights) because the analyses are post-hoc and sustained commercial success depends on reimbursement and persistent efficacy